Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study

Journal of Clinical Gastroenterology

Volumn 48, Issue , 2014, Pages S102-S105

  Murina, Filippo ^a   Graziottin, Alessandra ^b   Vicariotto, Franco ^c   De Seta, Francesco ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Gynaecology Unit   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Biofilms; Lactobacilli; Recurrent vulvovaginal candidiasis; Vaginal microbiota; Vulvovaginal candidosis

Indexed keywords

AGENTS USED INTRAVAGINALLY; ANTIFUNGAL AGENT; DSM 19187; DSM 21717; FLUCONAZOLE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; PROBIOTIC AGENT; TABLET;

ADULT; CONFERENCE PAPER; DRUG EFFICACY; DRUG WITHDRAWAL; EFFERVESCENT TABLET; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; IN VIVO STUDY; INFECTION PREVENTION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS FERMENTUM; MAJOR CLINICAL STUDY; MICROENVIRONMENT; NONHUMAN; PRIMARY PREVENTION; RECURRENT INFECTION; SECONDARY PREVENTION; SLOW RELEASE FORMULATION; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA CANDIDIASIS; VAGINAL BURNING SENSATION; BIOFILM; CANDIDIASIS, VULVOVAGINAL; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; GROWTH, DEVELOPMENT AND AGING; INTRAVAGINAL DRUG ADMINISTRATION; ITALY; MICROBIOLOGY; MIDDLE AGED; RECURRENT DISEASE; TABLET; TIME; TREATMENT OUTCOME; VAGINA; VULVA; YOUNG ADULT;

ADMINISTRATION, INTRAVAGINAL; ADULT; BIOFILMS; CANDIDIASIS, VULVOVAGINAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ITALY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS FERMENTUM; MIDDLE AGED; PROBIOTICS; RECURRENCE; TABLETS; TIME FACTORS; TREATMENT OUTCOME; VAGINA; VULVA; YOUNG ADULT;

EID: 84916625664     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000225     Document Type: Conference Paper

References (15)

1. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369: 1961-1971.
2. Cetin M, Ocak S, Gungoren A, et al. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis. 2007;7:584-588.
3. Vazquez JA, Sobel JD, Demitriou R, et al. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis. 1994;170: 1566-1569.
4. Sobel JD, Wiesenfeld HC, Martens M. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351:876-883.
5. Donders G, Bellen G, Byttebier G, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008;199:613.e1-613.e9.
6. Aroutcheva A, Gariti D, Simon M, et al. Defense factors of vaginal lactobacilli. Am J Obstet Gynecol. 2001;185:375-379.
7. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001;185:363-369.
8. Barousse MM, Espinosa T, Dunlap K, et al. Vaginal epithelial cell anti-Candida albicans activity is associated with protection against symptomatic vaginal candidiasis. Infect Immun. 2005;73:7765-7767.
9. Steele C, Fidel PL Jr. Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infect Immun. 2002;70:577-583.
10. Chassot F, Negri MFN, Svidzinski AE, et al. Can intrauterine contraceptive devices be a Candida albicans reservoir? Contraception. 2008;77:355-359.
11. Martinez R, Seney S, Summers K, et al. Effect of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and induce inflammation. Microbiol Immunol. 2009;53:487-495.
12. Pascual LM, Daniele MB, Ruiz F, et al. Lactobacillus rhamnosus L60, a potential probiotic isolated from the human vagina. J Gen Appl Microbiol. 2008;54:141-148.
13. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother. 2006;58:266-272.
14. Vicariotto F, Del Piano M, Mogna L, et al. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012;46:S73-S80.
15. McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86:58-64.